The rapid adoption of GLP-1 receptor agonists has reshaped obesity treatment, but a critical question has emerged: if weight loss is now pharmacologically achievable, does structured physical activity still carry independent value? The American Heart Association's new scientific statement answers with a clear yes — and the reasoning extends well beyond calorie balance.
The AHA statement, published in a major cardiology context and covered by JAMA, draws on accumulated evidence to argue that physical activity contributes to obesity care through mechanisms distinct from those targeted by semaglutide or tirzepatide. A central concern involves body composition: GLP-1 agonists drive weight loss that includes a substantial proportion of lean muscle mass — potentially 25–40% of total weight lost in some analyses — whereas resistance and aerobic exercise help preserve or rebuild skeletal muscle during caloric deficit. The statement also highlights cardiorespiratory fitness as an independent mortality predictor, one that drug-induced weight loss alone does not reliably improve. Physical activity further affects insulin sensitivity, inflammatory markers, and mental health outcomes through pathways the drugs do not fully replicate.
This guidance arrives at a pivotal moment for clinical practice. GLP-1 drugs have achieved what decades of behavioral interventions could not — consistent, significant weight reduction at scale — but the field is now grappling with what is lost in purely pharmacological approaches. The muscle mass concern is not trivial; sarcopenic obesity carries elevated cardiovascular and metabolic risk, and older adults on these agents face particular vulnerability. The AHA statement is unlikely to be paradigm-shifting for exercise scientists, who have long documented fitness benefits independent of weight, but it carries important clinical weight by formally embedding physical activity into obesity pharmacotherapy protocols. The key limitation is that most supporting trials were not designed around GLP-1 co-treatment, leaving the optimal exercise type, dose, and timing alongside these agents still largely unresolved.